In8bio Inc (INAB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.04 (-2.80%), Market cap $0.01B, 52-week low–high $0.12 ~ $4.17.
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamm
Financial statements, price targets, institutional (13F) holdings and related news for In8bio Inc are updated in real time on BlackAll Trade.
In8bio Inc trades at $1.04 (-2.80%). Real-time quotes and charts are available on BlackAll Trade.
In8bio Inc has a market cap of about $0.01B.
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmu